BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15225437)

  • 1. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].
    Shin YM; Heo J; Kim GH; Kang DH; Song GA; Cho M; Yang US; Kim CM; Park HK; Jang HJ
    Taehan Kan Hakhoe Chi; 2003 Mar; 9(1):1-9. PubMed ID: 12657823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
    Akuta N; Suzuki F; Kobayashi M; Matsuda M; Sato J; Takagi K; Tsubota A; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY; Sabahi F; Amini-Bavil-Olyaee S; Alavian SM; Merat S
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.
    Liu KZ; Hou W; Zumbika E; Ni Q
    J Zhejiang Univ Sci B; 2005 Dec; 6(12):1182-7. PubMed ID: 16358376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection and identification of emergence of HBV YMDD motif mutation during lamivudine treatment by hybridization to an oligonucleotide array].
    Zhao W; Liu W; Liu QJ; Zhang L; Zhang HR; Liu XJ; Zhou ZX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Dec; 17(4):339-43. PubMed ID: 15340547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.